A 38-year-old woman from Delhi presents with vaginal bleeding and pelvic pain. Cervical biopsy confirms stage IIB squamous cell carcinoma of the cervix (4.5 cm lesion with parametrial invasion). Staging workup including chest X-ray, abdominal ultrasound, and pelvic MRI shows no distant metastases. She has no contraindications to chemotherapy or radiation. What is the most appropriate primary treatment for this patient?

Explanation

## Management of Stage IIB Cervical Cancer **Key Point:** Stage IIB cervical cancer (parametrial invasion) is NOT amenable to surgery as primary treatment. Concurrent chemoradiation therapy (CCRT) with brachytherapy is the gold standard. ### Why Surgery Is Not an Option for Stage IIB | Reason | Explanation | |--------|-------------| | Parametrial invasion | Precludes adequate surgical margins | | Risk of incomplete resection | Tumor extends into parametrium, making radical hysterectomy inadequate | | Increased morbidity | Extensive surgery with poor oncologic outcome | ### Standard Treatment Algorithm for Stage IIB ```mermaid flowchart TD A["Stage IIB Cervical Cancer<br/>(Parametrial invasion)"]:::outcome --> B{"Candidate for<br/>chemotherapy?"}:::decision B -->|"Yes"| C["CCRT<br/>(Cisplatin 40 mg/m² weekly)"]:::action B -->|"No"| D["EBRT alone"]:::action C --> E["Intracavitary Brachytherapy<br/>(Point A dose)"]:::action D --> F["Brachytherapy"]:::action E --> G["Improved DFS & OS"]:::outcome F --> H["Lower cure rate"]:::outcome ``` ### Evidence for CCRT + Brachytherapy **High-Yield:** Multiple randomized trials (RTOG 90-01, GOG 165, SWOG) demonstrate that concurrent cisplatin-based chemotherapy with EBRT improves both disease-free survival (DFS) and overall survival (OS) by ~10–15% compared to EBRT alone in stages IIB–IVA cervical cancer. **Clinical Pearl:** Cisplatin is the preferred radiosensitizing agent at a dose of 40 mg/m² weekly during EBRT. The combination works by: 1. Direct cytotoxic effect of chemotherapy 2. Radiosensitization (inhibition of DNA repair) 3. Systemic control of micrometastases ### Brachytherapy Component - **Timing:** Initiated after completion of EBRT (typically 4–6 weeks after start of CCRT) - **Dose:** Point A dose of 75–85 Gy (EQD2) is the target - **Modality:** Low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy - **Purpose:** Delivers high local dose to the primary tumor while sparing surrounding tissues **Mnemonic:** CCRT + BRACHY = Stage IIB. (Chemo + Radiation + Brachytherapy) ### Why Not Other Options? - **Radical hysterectomy:** Parametrial invasion makes this inadequate; surgery is reserved for stage IB (no parametrial involvement). - **EBRT alone:** Inferior outcomes compared to CCRT; reserved only for patients unfit for chemotherapy. - **Neoadjuvant chemotherapy + surgery:** No evidence supports this approach; CCRT + brachytherapy is standard. [cite:NCCN Guidelines Cervical Cancer 2023; GOG 165 Trial, J Clin Oncol 1999]